Antitrust probes singe Indian pharma

Several Indian pharmaceutical companies are facing the dual challenges of antitrust investigations and being sued by multinational pharmaceutical companies. There has been an increase in probes by the US regulator for possible market failures, such as failure to follow good manufacturing practices and deviations from the regulatory path, in the past few months, with multiple cases scorching the growth plans of Indian drug companies, reports The Pharma Letter’s India correspondent.

A lawsuit recently named Dr Reddy's Laboratories (BSE: 500124) and several other generic companies as defendants for lymphoma generic of Celgene’s Revlimid (lenalidomide).

The complaint filed in New Jersey on November 18 against Dr Reddy's, Celgene, Bristol Myers Squibb (NYSE: BMS; which subsequently acquired Celgene), and several other generic companies alleges that the companies improperly restrained competition for the generics and maintained a shared monopoly. The complaint also alleges that the companies sought to delay generic entry until 2026.